New drug ARGX-109 put to the test in healthy volunteers
NCT ID NCT06799416
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This early-stage study tested the safety of a single dose of ARGX-109 in 40 healthy adults aged 18 to 65. Researchers also measured how the drug moves through the body and how it affects immune signals. No treatment was given for any disease; the goal was simply to gather initial safety data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences - Montreal - Phase I unit
Mount Royal, Quebec, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.